SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-053535
Filing Date
2024-05-06
Accepted
2024-05-06 16:05:36
Documents
62
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q stok-20240331.htm   iXBRL 10-Q 1584239
2 EX-31.1 stok-ex31_1.htm EX-31.1 15376
3 EX-31.2 stok-ex31_2.htm EX-31.2 15202
4 EX-32.1 stok-ex32_1.htm EX-32.1 7760
5 EX-32.2 stok-ex32_2.htm EX-32.2 8558
6 GRAPHIC img145339505_0.jpg GRAPHIC 28944
7 GRAPHIC img145339505_1.jpg GRAPHIC 21998
8 GRAPHIC img145339505_2.jpg GRAPHIC 26494
  Complete submission text file 0000950170-24-053535.txt   5649750

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT stok-20240331.xsd EX-101.SCH 719174
65 EXTRACTED XBRL INSTANCE DOCUMENT stok-20240331_htm.xml XML 704881
Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Filer) CIK: 0001623526 (see all company filings)

IRS No.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38938 | Film No.: 24917484
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)